Association of Polymorphisms in Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), and Renin (REN) with Recurrent Pregnancy Loss in Korean Women

被引:5
|
作者
Cho, Hee Young [1 ]
Park, Han Sung [2 ]
Ahn, Eun Hee [3 ]
Ko, Eun Ju [2 ]
Park, Hyeon Woo [2 ]
Kim, Young Ran [3 ]
Kim, Ji Hyang [3 ]
Lee, Woo Sik [4 ]
Kim, Nam Keun [2 ]
机构
[1] CHA Univ, Dept Obstet & Gynecol, CHA Gangnam Med Ctr, Seoul 06135, South Korea
[2] CHA Univ, Dept Biomed Sci, Coll Life Sci, Seongnam 13488, South Korea
[3] CHA Univ, Dept Obstet & Gynecol, CHA Bundang Med Ctr, Seongnam 13496, South Korea
[4] CHA Univ, Fertil Ctr, CHA Gangnam Med Ctr, Seoul 06135, South Korea
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 12期
基金
新加坡国家研究基金会;
关键词
plasminogen activator inhibitor-1; tissue plasminogen activator; renin; polymorphism; recurrent pregnancy loss; CORONARY-ARTERY-DISEASE; GENE POLYMORPHISM; T-PA; ANGIOTENSIN; RISK; INFLAMMATION; VARIANTS; RELEASE; SYSTEM; TYPE-1;
D O I
10.3390/jpm11121378
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Recurrent pregnancy loss (RPL) is defined as two or more consecutive pregnancy losses prior to 20 weeks of gestational age. Various factors, including immune dysfunction, endocrine disorders, coagulation abnormality, and genetic disorders influence RPL. In particular, plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), and renin (REN) have important roles in the thrombotic and thrombolytic systems, and abnormal expression of these genes have a reported negative correlation with pregnancy maintenance. Moreover, some polymorphisms of the three genes are related to expression levels and thrombotic disorder. Therefore, we investigated whether polymorphisms of PAI-1, tPA, and REN are linked to RPL. Genotyping of the six polymorphisms (PAI-1 rs11178, rs1050955, tPA rs4646972, rs2020918, REN rs1464816, and rs5707) was performed using polymerase chain reaction (PCR)-restriction fragment length polymorphism and associations of the polymorphisms with RPL were evaluated by statistical analysis. The polymorphism PAI-1 rs1050955 GA+AA was associated with decreased RPL risk (AOR, 0.528; 95% CI 0.356-0.781; p = 0.001) as was the REN 10795 rs5707 GG genotype (AOR, 0.487; 95% CI 0.301-0.787; p = 0.003). In contrast, the tPA rs4646972 II genotype correlated with increased RPL risk (AOR, 1.606; 95% CI, 1.047-2.463; p = 0.030). This study provides evidence that tPA Alu rs4646972 may contribute to the risk of idiopathic RPL, but PAI-1 12068 rs1050955 and REN 10795 rs5707 are associated with a decreased risk of RPL. Therefore, these alleles may be useful as biomarkers to evaluate the risk of RPL.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Imbalance of Plasminogen Activator Inhibitor Type-1 (PAI-1) and Tissue Plasminogen Activator (t-PA) Activity in Patients With Noonan Syndrome
    Mehta, Parth
    Parker, Robert I.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (07) : 532 - 536
  • [22] Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study
    Bosnyak, Z
    Forrest, KYZ
    Maser, RE
    Becker, D
    Orchard, TJ
    DIABETIC MEDICINE, 2003, 20 (02) : 147 - 151
  • [23] Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects
    Al-Hamodi, Zaid
    Saif-Ali, Riyadh
    Ismail, Ikram S.
    Ahmed, Khaled A.
    Muniandy, Sekaran
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2012,
  • [24] Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction
    Ganti, AK
    Potti, A
    Yegnanarayan, R
    PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2002, 32 (02) : 80 - 84
  • [25] Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Patients with Acute Paraquat Intoxication
    Seok, Su-Jin
    Kim, Su-Ji
    Gil, Hyo-Wook
    Yang, Jong-Oh
    Lee, Eun-Young
    Hong, Sae-Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (04) : 474 - 481
  • [26] Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schonlein purpura
    Besbas, N
    Erbay, A
    Saatci, U
    Ozdemir, S
    Bakkaloglu, A
    Ozen, S
    Topaloglu, R
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1998, 16 (01) : 95 - 98
  • [27] Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility
    Xin Hu
    Xin Zan
    Zhiyi Xie
    Yunke Li
    Sen Lin
    Hao Li
    Chao You
    Molecular Neurobiology, 2017, 54 : 328 - 341
  • [28] Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer - Relationship with Clinical Outcome
    Ferroni, Patrizia
    Roselli, Mario
    Portarena, Ilaria
    Formica, Vincenzo
    Riondino, Silvia
    La Farina, Francesca
    Costarelli, Leopoldo
    Melino, Antonia
    Massimiani, Gioia
    Cavaliere, Francesco
    Palmirotta, Raffaele
    Guadagni, Fiorella
    ANTICANCER RESEARCH, 2014, 34 (03) : 1153 - 1161
  • [29] Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Al-Hamodi, Zaid
    Ismail, Ikram S.
    Saif-Ali, Riyadh
    Ahmed, Khaled A.
    Muniandy, Sekaran
    CARDIOVASCULAR DIABETOLOGY, 2011, 10
  • [30] Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture
    Xu, Zhi
    Castellino, Francis J.
    Ploplis, Victoria A.
    BLOOD, 2010, 115 (10) : 2038 - 2047